American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products

Fri, 05/01/2009 - 4:34am
The American Academyof Dermatology (Academy) today issued a statement in response to the U.S. Foodand Drug Administration's (FDA) announcement that a box warning will be addedto the labeling of botulinum toxin products and a medication guide will bedistributed to patients receiving these products for any use. These productsare FDA-approved for the treatment of frown lines between the eyebrows andsevere underarm sweating (hyperhidrosis). "The health, safety and welfare of our patients being treated withbotulinum toxin products are of paramount importance to dermatologists," saiddermatologist David M. Pariser, MD, president of the American Academy ofDermatology. "While no serious side effects have been reported from thedermatologic use of botulinum toxin products, the FDA's actions emphasize theimportance of selecting a qualified physician to administer these products formedical and cosmetic uses."

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.